Cited 15 times in
Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최준용 | - |
dc.date.accessioned | 2023-03-10T01:29:23Z | - |
dc.date.available | 2023-03-10T01:29:23Z | - |
dc.date.issued | 2022-10 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/193187 | - |
dc.description.abstract | Omicron has become the globally dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, creating additional challenges due to its ability to evade neutralization. Here, we report that neutralizing antibodies against Omicron variants are undetected following COVID-19 infection with ancestral or past SARS-CoV-2 variant viruses or after two-dose mRNA vaccination. Compared with two-dose vaccination, a three-dose vaccination course induces broad neutralizing antibody responses with improved durability against different SARS-CoV-2 variants, although neutralizing antibody titers against Omicron remain low. Intriguingly, among individuals with three-dose vaccination, Omicron breakthrough infection substantially augments serum neutralizing activity against a broad spectrum of SARS-CoV-2 variants, including Omicron variants BA.1, BA.2, and BA.5. Additionally, after Omicron breakthrough infection, memory T cells respond to the spike proteins of both ancestral and Omicron SARS-CoV-2 by producing cytokines with polyfunctionality. These results suggest that Omicron breakthrough infection following three-dose mRNA vaccination induces pan-SARS-CoV-2 immunity that may protect against emerging SARS-CoV-2 variants of concern. Keywords: D614G; Omicron BA.1; Omicron BA.2; SARS-CoV-2; T cell immune response; ancestral; | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Cell Press | - |
dc.relation.isPartOf | CELL REPORTS MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antibodies, Viral | - |
dc.subject.MESH | Antibody Formation | - |
dc.subject.MESH | Broadly Neutralizing Antibodies | - |
dc.subject.MESH | COVID-19* / prevention & control | - |
dc.subject.MESH | Cytokines | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | RNA, Messenger | - |
dc.subject.MESH | SARS-CoV-2* / genetics | - |
dc.subject.MESH | Spike Glycoprotein, Coronavirus / genetics | - |
dc.subject.MESH | Viral Envelope Proteins / genetics | - |
dc.title | Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hye Won Jeong | - |
dc.contributor.googleauthor | Se-Mi Kim | - |
dc.contributor.googleauthor | Min Kyung Jung | - |
dc.contributor.googleauthor | Ji Yun Noh | - |
dc.contributor.googleauthor | Ji-Seung Yoo | - |
dc.contributor.googleauthor | Eun-Ha Kim | - |
dc.contributor.googleauthor | Young-Il Kim | - |
dc.contributor.googleauthor | Kwangmin Yu | - |
dc.contributor.googleauthor | Seung-Gyu Jang | - |
dc.contributor.googleauthor | Juryeon Gil | - |
dc.contributor.googleauthor | Mark Anthony Casel | - |
dc.contributor.googleauthor | Rollon Rare | - |
dc.contributor.googleauthor | Jeong Ho Choi | - |
dc.contributor.googleauthor | Hee-Sung Kim | - |
dc.contributor.googleauthor | Jun Hyoung Kim | - |
dc.contributor.googleauthor | Jihye Um | - |
dc.contributor.googleauthor | Chaeyoon Kim | - |
dc.contributor.googleauthor | Yeonjae Kim | - |
dc.contributor.googleauthor | Bum Sik Chin | - |
dc.contributor.googleauthor | Sungmin Jung | - |
dc.contributor.googleauthor | Jun Yong Choi | - |
dc.contributor.googleauthor | Kyoung-Ho Song | - |
dc.contributor.googleauthor | Yong-Dae Kim | - |
dc.contributor.googleauthor | Jun-Sun Park | - |
dc.contributor.googleauthor | Joon Young Song | - |
dc.contributor.googleauthor | Eui-Cheol Shin | - |
dc.contributor.googleauthor | Young Ki Choi | - |
dc.identifier.doi | 10.1016/j.xcrm.2022.100764 | - |
dc.contributor.localId | A04191 | - |
dc.relation.journalcode | J04379 | - |
dc.identifier.eissn | 2666-3791 | - |
dc.identifier.pmid | 36182684 | - |
dc.subject.keyword | D614G | - |
dc.subject.keyword | Omicron BA.1 | - |
dc.subject.keyword | Omicron BA.2 | - |
dc.subject.keyword | SARS-CoV-2 | - |
dc.subject.keyword | T cell immune response | - |
dc.subject.keyword | ancestral | - |
dc.subject.keyword | breakthrough infection | - |
dc.subject.keyword | cross-neutralizatio | - |
dc.subject.keyword | mRNA vaccine | - |
dc.subject.keyword | recovered patient | - |
dc.subject.keyword | variants of concern | - |
dc.contributor.alternativeName | Choi, Jun Yong | - |
dc.contributor.affiliatedAuthor | 최준용 | - |
dc.citation.volume | 3 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 100764 | - |
dc.identifier.bibliographicCitation | CELL REPORTS MEDICINE, Vol.3(10) : 100764, 2022-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.